Article3 Biotech2018
Pathway engineering in
Article in 3 Biotech, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production inSynthetic and systems biotechnology · 2026Article
- On the Possibility of Using 5-Aminolevulinic Acid in the Light-Induced Destruction of Microorganisms.International journal of molecular sciences · 2024Review
- MeJA-mediated enhancement of salt-tolerance of Populus wutunensis by 5-aminolevulinic acid.BMC plant biology · 2023Article
- A Non-functional γ-Aminobutyric Acid Shunt Pathway in CyanobacteriumInternational journal of molecular sciences · 2023Article
- Synthetic biology tools for engineeringComputational and structural biotechnology journal · 2023Review
- Transcriptomic and enzymatic analysis reveals the roles of glutamate dehydrogenase in Corynebacterium glutamicum.AMB Express · 2022Article
- Natural 5-Aminolevulinic Acid: Sources, Biosynthesis, Detection and Applications.Frontiers in bioengineering and biotechnology · 2022Review
- Modular control of multiple pathways of Corynebacterium glutamicum for 5-aminolevulinic acid production.AMB Express · 2021Article
- Production of l-glutamate family amino acids inSynthetic and systems biotechnology · 2021Review
- Challenges and opportunities of bioprocessing 5-aminolevulinic acid using genetic and metabolic engineering: a critical review.Bioresources and bioprocessing · 2021Review
- Downregulating of hemB via synthetic antisense RNAs for improving 5-aminolevulinic acid production in3 Biotech · 2021Article
- Recent progress in production of amino acid-derived chemicals using Corynebacterium glutamicum.World journal of microbiology & biotechnology · 2021Review
- Proteome analysis guided genetic engineering of Corynebacterium glutamicum S9114 for tween 40-triggered improvement in L-ornithine production.Microbial cell factories · 2020Article
- Efficient bioproduction of 5-aminolevulinic acid, a promising biostimulant and nutrient, from renewable bioresources by engineeredBiotechnology for biofuels · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
5-Aminolevulinic acid (ALA) is a non-protein amino acid with a significant potential for cancer treatment and plant stress resistance. Microbial fermentation has gradually replaced the traditional chemical-based method for ALA production, thus increasing the need for high-ALA-producing strains. In this study, we engineered the glutamate producing strain,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.